PIN29 Economic Burden of Varicella and Cost Estimates of a Varicella National Immunization Program in Denmark

Pawaskar, Manjiri; Samant, Salome; Flem, Elmira; Birck, A.M.; Benčina, Goran

doi:10.1016/j.jval.2020.08.870

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A budget impact analysis for Denmark [ 26 ] showed that the cost of implementation of two-dose UVV program with Varivax® was €5.29–6.76 million depending on vaccination coverage and vaccine cost. This is less than the annual cost of €7.23 million associated with the disease in Denmark [ 91 ]. Some disease models have predicted an increase in HZ after implementing UVV programs due to a reduction in circulating VZV [ 92 – 94 ].…”

Section: Discussionmentioning

confidence: 99%

Economic burden of varicella in Europe in the absence of universal varicella vaccination

Pawaskar

Meroc²,

Samant

et al. 2021

BMC Public Health

View full text Add to dashboard Cite

Background Though the disease burden of varicella in Europe has been reported previously, the economic burden is still unknown. This study estimated the economic burden of varicella in Europe in the absence of Universal Varicella Vaccination (UVV) in 2018 Euros from both payer (direct costs) and societal (direct and indirect costs) perspectives. Methods We estimated the country specific and overall annual costs of varicella in absence of UVV in 31 European countries (27 EU countries, plus Iceland, Norway, Switzerland and the United Kingdom). To obtain country specific unit costs and associated healthcare utilization, we conducted a systematic literature review, searching in PubMed, EMBASE, NEED, DARE, REPEC, Open Grey, and public heath websites (1/1/1999–10/15/2019). The number of annual varicella cases, deaths, outpatient visits and hospitalizations were calculated (without UVV) based on age-specific incidence rates (Riera-Montes et al. 2017) and 2018 population data by country. Unit cost per varicella case and disease burden data were combined using stochastic modeling to estimate 2018 costs stratified by country, age and healthcare resource. Results Overall annual total costs associated with varicella were estimated to be €662,592,061 (Range: €309,552,363 to €1,015,631,760) in Europe in absence of UVV. Direct and indirect costs were estimated at €229,076,206 (Range €144,809,557 to €313,342,856) and €433,515,855 (Range €164,742,806 to €702,288,904), respectively. Total cost per case was €121.45 (direct: €41.99; indirect: €79.46). Almost half of the costs were attributed to cases in children under 5 years, owing mainly to caregiver work loss. The distribution of costs by healthcare resource was similar across countries. France and Germany accounted for 49.28% of total annual costs, most likely due to a combination of high numbers of cases and unit costs in these countries. Conclusions The economic burden of varicella across Europe in the absence of UVV is substantial (over 600 M€), primarily driven by caregiver burden including work productivity losses.

show abstract

Section: Discussionmentioning

confidence: 99%